Status:
In progress
Technology type:
Medicine
Decision:
Selected
Reason for decision:
Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process:
STA Standard
ID number:
6497

Provisional Schedule

Committee meeting: 1:
11 November 2025
Expected publication:
28 January 2026

Project Team

Project lead
Leena Issa

Email enquiries

If you have any queries please email [email protected]

Stakeholders

Companies sponsors
SIFI S.p.a. (polihexanide)
Others
Department of Health and Social Care
 
NHS England
Patient carer groups
Fight for Sight
Professional groups
Association of Optometrists
 
Neonatal and Paediatric Pharmacists Group
 
Royal College of Ophthalmologists
 
Royal College of Physicians
Associated public health groups
None
Comparator companies
Thorton & Ross Ltd (propamidine) (confidentiality agreement not signed, not participating)
General commentators
All Wales Therapeutics and Toxicology Centre
 
British National Formulary
 
Department of Health - Northern Ireland
 
Healthcare Improvement Scotland
 
Medicines and Healthcare products Regulatory Agency
 
NHS Wales Joint Commissioning Committee
 
Scottish Medicines Consortium
 
Welsh Government
Relevant research groups
None

Timeline

Key events during the development of the guidance:

Date Update
11 April 2025 Invitation to participate
26 March 2025 Topic routing was discussed at the NICE Prioritisation Board in March 2025. The Board concluded that the topic was suitable for a Technology Appraisal. Please see project documents for further details.
26 March 2025 Topic selection
22 January 2025 - 19 February 2025 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: ID6497
22 January 2025 In progress. Scoping commenced.
25 October 2024 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual